Sentences with phrase «therapeutic factors associated»

Could Yalom's ideas about the therapeutic factors associated with group psychotherapy be used to help social psychologists move past the stubborn problem of task group inefficiency?

Not exact matches

Actual results and the timing of events could differ materially from those anticipated in the forward - looking statements due to these risks and uncertainties as well as other factors, which include, without limitation: the uncertain timing of, and risks relating to, the executive search process; risks related to the potential failure of eptinezumab to demonstrate safety and efficacy in clinical testing; Alder's ability to conduct clinical trials and studies of eptinezumab sufficient to achieve a positive completion; the availability of data at the expected times; the clinical, therapeutic and commercial value of eptinezumab; risks and uncertainties related to regulatory application, review and approval processes and Alder's compliance with applicable legal and regulatory requirements; risks and uncertainties relating to the manufacture of eptinezumab; Alder's ability to obtain and protect intellectual property rights, and operate without infringing on the intellectual property rights of others; the uncertain timing and level of expenses associated with Alder's development and commercialization activities; the sufficiency of Alder's capital and other resources; market competition; changes in economic and business conditions; and other factors discussed under the caption «Risk Factors» in Alder's Annual Report on Form 10 - K for the fiscal year ended December 31, 2017, which was filed with the Securities and Exchange Commission (SEC) on February 26, 2018, and is available on the SEC's website at www.sfactors, which include, without limitation: the uncertain timing of, and risks relating to, the executive search process; risks related to the potential failure of eptinezumab to demonstrate safety and efficacy in clinical testing; Alder's ability to conduct clinical trials and studies of eptinezumab sufficient to achieve a positive completion; the availability of data at the expected times; the clinical, therapeutic and commercial value of eptinezumab; risks and uncertainties related to regulatory application, review and approval processes and Alder's compliance with applicable legal and regulatory requirements; risks and uncertainties relating to the manufacture of eptinezumab; Alder's ability to obtain and protect intellectual property rights, and operate without infringing on the intellectual property rights of others; the uncertain timing and level of expenses associated with Alder's development and commercialization activities; the sufficiency of Alder's capital and other resources; market competition; changes in economic and business conditions; and other factors discussed under the caption «Risk Factors» in Alder's Annual Report on Form 10 - K for the fiscal year ended December 31, 2017, which was filed with the Securities and Exchange Commission (SEC) on February 26, 2018, and is available on the SEC's website at www.sfactors discussed under the caption «Risk Factors» in Alder's Annual Report on Form 10 - K for the fiscal year ended December 31, 2017, which was filed with the Securities and Exchange Commission (SEC) on February 26, 2018, and is available on the SEC's website at www.sFactors» in Alder's Annual Report on Form 10 - K for the fiscal year ended December 31, 2017, which was filed with the Securities and Exchange Commission (SEC) on February 26, 2018, and is available on the SEC's website at www.sec.gov.

«Our findings suggest that PRMT5 is a possible prognostic factor and therapeutic target for glioblastoma, and they provide a rationale for developing agents that target PRMT5 in this deadly disease,» says co-corresponding author Robert A. Baiocchi, MD, PhD, associate professor of medicine and a hematologist at the OSUCCC — James who is also collaborating on an Ohio State effort to develop a PMRT5 inhibitor.

However, these problems associated with histocompatibility may be solved using autologous donor adult stem cells, therapeutic cloning, stem cell banks or more recently by reprogramming of somatic cells with defined factors (e.g. induced pluripotent stem cells).

Through these studies he has identified a new transcription factor and associated pathway that could yield new avenues for therapeutic intervention in SMA.

Elevated plasma TG levels represent a risk factor for CVD in humans, and an adjusted analysis of patients in the Framingham Heart Study suggests that each decrease of 1 mg / dl in plasma ApoC - III levels is associated with a 4 % decrease in CVD risk (11), further supporting the potential therapeutic benefit of suppressing plasma ApoC - III levels in humans to reduce CVD.

1935 Effects of the high carbohydrate - low calorie diet upon carbohydrate tolerance in diabetes mellitus 1955 Low - fat diet and therapeutic doses of insulin in diabetes mellitus 1958 Effect of rice diet on diabetes mellitus associated with vascular disease 1976 Beneficial effects of a high carbohydrate, high fiber diet on hyperglycemic diabetic men 1977 Effect of carbohydrate restriction and high carbohydrates diets on men with chemical diabetes 1979 High - carbohydrate, high - fiber diets for insulin - treated men with diabetes mellitus 1981 High carbohydrate high in fibre diet in diabetes 1982 Response of non-insulin-dependent diabetic patients to an intensive program of diet and exercise 1983 Long - term use of a high - complex - carbohydrate, high - fiber, low - fat diet and exercise in the treatment of NIDDM patients 1994 Diet and exercise in the treatment of NIDDM: the need for early emphasis 1999 Toward improved management of NIDDM: A randomized, controlled, pilot intervention using a lowfat, vegetarian diet 2005 The effects of a low - fat, plant - based dietary intervention on body weight, metabolism, and insulin sensitivity 2006 A low - fat vegan diet improves glycemic control and cardiovascular risk factors in a randomized clinical trial in individuals with type 2 diabetes 2006 Effect of short ‐ term Pritikin diet therapy on the metabolic syndrome 2009 A low - fat vegan diet and a conventional diabetes diet in the treatment of type 2 diabetes: a randomized, controlled, 74 - wk clinical trial

The fact that many children and youth may not be ready for formal talk therapy does not mean that therapeutic benefits do not take place, and it certainly does not imply that the two most powerful common factors associated with change (outside of talk therapy events in the lives of clients, and relationship factors), also do not occur with precontemplative children and young people.